The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 18th 2025
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
High White Blood Cell Counts Are Associated With Long-Term Acute COPD Exacerbations, Study Says
January 13th 2024The study's findings suggest that high baseline white blood cell count, particularly high neutrophil count, was associated with a higher incidence of long-term acute exacerbation of chronic obstructive pulmonary disease (COPD).
Read More
Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL
January 12th 2024A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Read More
Health State Utility Scores for DMD-Related Impairment Need to Better Reflect Patient Input
January 12th 2024Patient-reported outcomes data regarding measures of health-related quality of life, also known as health state utilities, in Duchenne muscular dystrophy (DMD) are scarce, with current knowledge in this area concentrated in caregiver feedback.
Read More
Hypofractionated Chemoradiation Regimen With an Adaptive SABR Boost Shows Promise in NSCLC
January 12th 2024An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC).
Read More
Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy
January 12th 2024A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
Watch
What Happens to Patients With Diabetes When Semaglutide Dosing Is Disrupted? Dr Ian Neeland Explains
January 11th 2024Possible long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events.
Watch
Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups
January 10th 2024Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
Read More
What We’re Reading: Doctor Payment Cuts; Menopause Drug; Student Mental Health Support
January 10th 2024Congress is being urged to reverse a cut to physicians’ Medicare payments; Bayer announced encouraging results on Monday of 2 phase 3 trials for its nonhormonal drug candidate meant to treat hot flashes; more students are turning to online mental health support rather than school counselors.
Read More
Dr Ian Neeland Explains Why Semaglutide Shortage Impacts Injectable and Not Oral Version
January 10th 2024According to Ian Neeland, MD, there are 2 main reasons for the shortage of injectable semaglutide: the fact that oral semaglutide has not yet been tested for weight loss, and that most practitioners just overlook it as an option.
Watch